Ticker > Company >

Arvee Laboratories share price

Arvee Laboratories (India) Ltd.

NSE: ARVEE SECTOR: Chemicals  33.05 K   25   2

228.32
+30.84 (15.62%)
NSE: 08 Dec 03:54 PM

Price Summary

Today's High

₹ 236

Today's Low

₹ 201

52 Week High

₹ 232.99

52 Week Low

₹ 126.54

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

251.61 Cr.

Enterprise Value

247.74 Cr.

No. of Shares

1.1 Cr.

P/E

624.34

P/B

8

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  28.53

CASH

4.91 Cr.

DEBT

1.03 Cr.

Promoter Holding

73.5 %

EPS (TTM)

₹  0.37

Sales Growth

26.83%

ROE

7.11 %

ROCE

10%

Profit Growth

104.15 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year26.83%
3 Year-1.54%
5 Year-3.26%

Profit Growth

1 Year104.15%
3 Year-5.86%
5 Year-1.36%

ROE%

1 Year7.11%
3 Year8.88%
5 Year10.28%

ROCE %

1 Year10%
3 Year13.46%
5 Year13.94%

Debt/Equity

0.0331

Price to Cash Flow

-1220.39

Interest Cover Ratio

12.5636

CFO/PAT (5 Yr. Avg.)

0.963684411391458

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Sep 2025 73.50 0.00
Jun 2025 73.50 0.00
Mar 2025 73.50 0.00
Dec 2024 73.50 0.00
Sep 2024 73.50 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 12.5636.
  • The company has an efficient Cash Conversion Cycle of 33.3977 days.
  • Company has a healthy liquidity position with current ratio of 5.1378.
  • The company has a high promoter holding of 73.5%.

 Limitations

  • The company has shown a poor profit growth of -5.86034866020143% for the Past 3 years.
  • The company has shown a poor revenue growth of -1.54482702003409% for the Past 3 years.
  • Company has negative cash flow from operations of -0.20617.
  • The company is trading at a high PE of 624.34.
  • The company is trading at a high EV/EBITDA of 133.9241.

Quarterly Result (All Figures in Cr.)

PARTICULARS Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025
Net Sales 12.53 8.91 6.45 7.48 3.45
Total Expenditure 11.02 8.56 6.23 7.14 3.32
Operating Profit 1.5 0.35 0.22 0.34 0.13
Other Income 0.16 0.19 0.21 0.17 0.23
Interest 0.05 0.05 0.07 0.04 0.04
Depreciation 0.3 0.28 0.27 0.29 0.3
Exceptional Items 0 0 0 0 0
Profit Before Tax 1.31 0.21 0.09 0.17 0.01
Tax 0.33 0.05 0.03 0.01 0
Profit After Tax 0.98 0.16 0.07 0.17 0.01
Adjusted EPS (Rs) 0.89 0.14 0.06 0.15 0.01

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 47.38 40.33 61.35 30.35 38.49
Total Expenditure 41.34 34.7 54.07 27.41 34.88
Operating Profit 6.04 5.62 7.28 2.94 3.61
Other Income 0.58 0.52 1.35 0.64 0.66
Interest 0.58 0.37 0.39 0.25 0.25
Depreciation 2.41 2.32 2.08 1.5 1.15
Exceptional Items 0 0 0 0 0
Profit Before Tax 3.64 3.45 6.17 1.83 2.87
Tax 0.96 0.88 2.05 0.78 0.72
Net Profit 2.68 2.57 4.12 1.05 2.15
Adjusted EPS (Rs.) 2.43 2.34 3.74 0.95 1.95

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 11.02 11.02 11.02 11.02 11.02
Total Reserves 10.42 12.92 17.04 18.09 20.24
Borrowings 1 1 1 1 1.03
Other N/C liabilities 0.31 0.2 0.78 1.32 1.45
Current liabilities 18.29 13.54 8.84 7.13 3.83
Total Liabilities 41.05 38.68 38.69 38.56 37.57
Assets
Net Block 13.81 13.84 12.68 12.67 15.27
Capital WIP 0.97 0.98 1.53 2.62 0.73
Intangible WIP 0 0 0 0 0
Investments 0 0 0 0 0
Loans & Advances 0.65 0.17 0.54 0.44 0.67
Other N/C Assets 0.07 0 2.36 5.85 1.24
Current Assets 25.55 23.69 21.57 16.98 19.66
Total Assets 41.05 38.68 38.69 38.56 37.57
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations 3.64 3.45 6.17 1.83 2.87
Adjustment 2.4 2.3 2.16 1.26 0.76
Changes in Assets & Liabilities -3.37 -0.78 -3.64 1 -3.26
Tax Paid -0.96 -0.95 -1.75 -0.43 -0.58
Operating Cash Flow 1.71 4.02 2.93 3.66 -0.21
Investing Cash Flow -0.6 0.06 -1.26 -2.16 -1.32
Financing Cash Flow 4.52 -6.05 -2.42 -0.19 -0.12
Net Cash Flow 5.63 -1.98 -0.75 1.31 -1.64

Corporate Actions

Investors Details

PARTICULARS Sep 2024% Dec 2024% Mar 2025% Jun 2025% Sep 2025%
promoters 73.50 73.50 73.50 73.50 73.50
chandrabalaben patel 0.02 0.02 0.02 0.02 0.02
forum saumil chokshi 0.02 0.02 0.02 0.02 0.02
kavita shalin chokshi 12.15 12.16 12.16 12.16 12.16
khushbuben shalinbhai pat... 0.02 0.02 0.02 0.02 0.02
mitaben bharatbhai choksh... 24.57 24.57 24.57 24.57 24.57
shalin sudhakarbhai patel... 36.68 36.68 36.68 36.68 36.68
shalinbhai sudhakarbhai p... 0.02 0.02 0.02 0.02 0.02
sudhakar chhotabhai patel... 0.02 0.02 0.02 0.02 0.02
shalin bharatbhai chokshi... 0.01 - - - -
PARTICULARS Sep 2024% Dec 2024% Mar 2025% Jun 2025% Sep 2025%
investors 26.50 26.50 26.50 26.50 26.50
deval pranav patel 5.19 5.19 5.19 5.19 5.19
gitaben dinehsbhai patel 9.98 9.98 9.98 9.98 9.98
jashbhai patel 4.79 4.79 4.79 4.79 4.79
madhuben jashbhai patel 3.70 3.70 3.70 3.70 3.70

Annual Reports

Title Link
Title Link
Annual Report 2024
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit CRISIL
Credit CRISIL
Credit CRISIL
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Concall related to this company.Report us
TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Presentation related to this company.Report us

Company News

Arvee Laboratories - Quaterly Results 12 Aug, 12:00 PM Arvee Laboratories - Quaterly Results 12 Aug, 12:00 PM Arvee Laboratories - Quaterly Results 12 Aug, 12:00 PM Arvee Laboratories - Quaterly Results 9 May, 12:00 PM Arvee Laboratories - Quaterly Results 9 May, 12:00 PM Arvee Laboratories - Quaterly Results 9 May, 12:00 PM Arvee Laboratories - Quaterly Results 12 Feb, 12:00 PM Arvee Laboratories - Quaterly Results 12 Feb, 12:00 PM Arvee Laboratories - Quaterly Results 13 Aug, 12:00 PM Arvee Laboratories - Quaterly Results 13 Aug, 12:00 PM Arvee Laboratories - Quaterly Results 17 May, 12:00 PM Arvee Laboratories - Quaterly Results 17 May, 12:00 PM Arvee Laboratories - Quaterly Results 13 Feb, 12:00 PM Arvee Laboratories - Quaterly Results 13 Feb, 12:00 PM Arvee Laboratories - Quaterly Results 11 Aug, 12:00 PM Arvee Laboratories - Quaterly Results 5 May, 12:00 PM Arvee Laboratories - Quaterly Results 5 May, 12:00 PM Arvee Laboratories - Quaterly Results 5 May, 12:00 PM Arvee Laboratories - Quaterly Results 2 Aug, 12:00 PM Arvee Laboratories - Quaterly Results 2 Aug, 12:00 PM Arvee Laboratories - Quaterly Results 2 Aug, 12:00 PM Arvee Laboratories - Quaterly Results 26 May, 12:00 PM Arvee Laboratories - Quaterly Results 26 May, 12:00 PM Arvee Laboratories - Quaterly Results 8 Feb, 12:00 PM Arvee Laboratories - Quaterly Results 8 Feb, 12:00 PM Arvee Laboratories - Quaterly Results 8 Feb, 12:00 PM Arvee Laboratories sells entire stake in ‘Arvee Speciality Chemicals’ 26 Mar, 3:55 PM

Arvee Laboratories Stock Price Analysis and Quick Research Report. Is Arvee Laboratories an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Arvee Laboratories. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Arvee Laboratories has a PE ratio of 624.336888159694 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Arvee Laboratories has ROA of 5.6406% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Arvee Laboratories has a Current ratio of 5.1378.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Arvee Laboratories has a ROE of 7.1133%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Arvee Laboratories has a Debt to Equity ratio of 0.0331 which means that the company has low proportion of debt in its capital.

  • Sales growth: Arvee Laboratories has reported revenue growth of 26.8314% which is fair in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Arvee Laboratories for the current financial year is 9.37848662987988%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Arvee Laboratories is Rs 0 and the yield is 0%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Arvee Laboratories is Rs 0.3657. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Arvee Laboratories in Ticker for free. Also, one can get the intrinsic value of Arvee Laboratories by using Valuation Calculators, which are available with a Finology ONE subscription. 

Arvee Laboratories FAQs

Q1. What is Arvee Laboratories share price today?
Ans: The current share price of Arvee Laboratories is Rs 228.32.

Q2. What is the market capitalisation of Arvee Laboratories?
Ans: Arvee Laboratories has a market capitalisation of Rs 251.60864 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Arvee Laboratories?
Ans: The PE ratio of Arvee Laboratories is 624.336888159694 and the P/B ratio of Arvee Laboratories is 8.00255161947222, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Arvee Laboratories share?
Ans: The 52-week high share price of Arvee Laboratories is Rs 232.99, and the 52-week low share price of Arvee Laboratories is Rs 126.54.

Q5. Does Arvee Laboratories pay dividends?
Ans: Currently, Arvee Laboratories does not pay dividends. Dividend yield of Arvee Laboratories is around 0%.

Q6. What are the face value and book value of Arvee Laboratories shares?
Ans: The face value of Arvee Laboratories shares is Rs 10, while the book value per share of Arvee Laboratories is around Rs 28.5309. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Arvee Laboratories?
Ans: Arvee Laboratories has a total debt of Rs 1.033275 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Arvee Laboratories?
Ans: The ROE of Arvee Laboratories is 7.1133% and ROCE of Arvee Laboratories is 9.9959%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Arvee Laboratories a good buy for the long term?
Ans: The Arvee Laboratories long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Arvee Laboratories undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Arvee Laboratories appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Arvee Laboratories’s financials?
Ans: You can review Arvee Laboratories’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Arvee Laboratories
X